Cover Image
市場調查報告書

植體抗宿主病 (GVHD)的全球市場 (2017-2027年):急性、慢性GVHD及預防

Global Graft versus Host Disease (GVHD) Market 2017-2027: Acute, Chronic and Prophylaxis GVHD

出版商 Visiongain Ltd 商品編碼 483047
出版日期 內容資訊 英文 162 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
植體抗宿主病 (GVHD)的全球市場 (2017-2027年):急性、慢性GVHD及預防 Global Graft versus Host Disease (GVHD) Market 2017-2027: Acute, Chronic and Prophylaxis GVHD
出版日期: 2017年02月10日 內容資訊: 英文 162 Pages
簡介

全球植體抗宿主病 (GVHD)的市場估計從2016年到2027年以6%的年複合成長率發展,從2016年的3億6000萬美元,成長到2026年的6億4000萬美元的規模。

本報告提供全球植體抗宿主病 (GVHD)的市場調查,GVHD的背景與分類,市場課題及市場機會分析,各產品的市場規模的變化與預測,各地區、主要國家的市場規模及患者數的變化與預測,主要的治療藥及新治療藥簡介,市場影響因素分析等彙整資料。

第1章 報告概要

第2章 植體抗宿主病 (GVHD)的背景

  • 定義
  • 分類
    • 急性GVHD
    • 慢性GVHD
    • GVHD的症狀
  • GVHD的等級

第3章 全球GVHD市場:成果

第4章 全球GVHD市場:預測

  • 主要調查結果
  • 市場課題、市場機會

第5章 市場分析、預測:各產品

第6章 市場分析、預測:各地區

  • 全球GVHD市場成果:各地區明細
  • 美國市場的預測
    • 市場預測:各產品
    • 患者數的預測
  • 日本市場預測
    • 市場預測:各產品
    • 患者數的預測
  • 法國市場預測
    • 市場預測:各產品
    • 患者數的預測
  • 德國市場預測
    • 市場預測:各產品
    • 患者數的預測
  • 義大利市場預測
    • 市場預測:各產品
    • 患者數的預測
  • 西班牙市場預測
    • 市場預測:各產品
    • 患者數的預測
  • 英國市場預測
    • 市場預測:各產品
    • 患者數的預測
  • 主要調查結果
  • 治療目標

第7章 主要GVHD治療藥的預測

  • Temcell HS
  • Remicade
  • Lemtrada
  • Velcade
  • Gleevac
  • Rapamune
  • Enbrel
  • Orencia
  • Nulojix
  • Grafalon (ATG-Fresenius S)
    • 簡介
    • 安全性、有效性
    • 優點及缺點
    • 整體銷售額的預測

第8章 新的GVHD治療藥的預測

  • Leukotac (inolimomab)
  • Begedina (begelomab)
  • Budesonide/Budenofalk (effeverscent)
    • 簡介
    • 臨床開發
    • 整體銷售額的預測

第9章 市場促進因素、障礙

第10章 SWOT分析

第11章 總論

圖表

目錄
Product Code: PHA0168

The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2021-2027. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in 2026.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 62 tables and 76 figures - all unavailable elsewhere.

The 162-page report provides clear detailed insight into the Graft versus Host Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Revenue and growth forecasts to 2027 for the global GVHD market
  • Revenue and growth forecasts to 2027 for the leading countries
  • GVHD patient number forecast to 2027 per leading country, segmented into total allogenic cases, first allogenic cases, acute GVHD and chronic GVHD
  • Revenue and growth forecasts to 2027 for the leading segments of the GVHD market by treatment type
  • Revenue and growth forecasts to 2027 for the leading drugs in the GVHD market.

Individual revenue forecasts to 2027 by treatment type:

  • Prophylaxis GVHD
  • Chronic GVHD
  • Acute GVHD

Individual revenue forecasts to 2027 by product:

  • Corticosteroids
  • Methylprednisolone
  • Budenofalk (effeverscent)
  • ATG therapies
    • Available ATG therapy (Thymoglobulin)
    • Atege-Fresenius
  • IL2Rα (CD25) inhibitors
    • Simulect (Basiliximab)
    • Leukotac (inolimomab)
  • TNFα inhibitors
    • Remicade (Infliximab)
    • Enbrel (Etanercept)
    • Co-stimulatory blockers
    • Orencia (abatacept)
    • Nulojix (belatacept)
  • Other biologics
    • Lemtrada (Alemtuzumab)
    • Rituxan/MabThera (rituximab)
    • Begedina (bt/9 anti-CD26)
  • Calcineurin inhibitors
    • Cyclosporine
  • mTOR inhibitors
    • Rapamune (sirolimus)
    • Certican (everolimus)
  • SOT therapies
    • CellCept/Myfortic (mycophenolate mofetil)
    • Prograf (tacrolimus)
  • Anti-neoplastic therapies
    • Velcade (bortezomib)
    • Gleevec (imatinib)
    • Methrotrexate
    • Nipent (pentostatin)
    • Cyclophosphamide
  • Stem Cell Treatments
    • In situ preparations of mesenchymal cells
    • Prochymal (remestemcel-L)
  • Extracorporeal Photophoresis
    • Uvadex (Therakos)

Individual revenue forecasts to 2027 by country, further segmented by treatment type and by product:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

GVHD patient number forecasts to 2027 per leading country, segmented into:

  • total allogenic cases
  • first allogenic cases
  • acute GVHD
  • chronic GVHD

Visiongain's study is intended for anyone requiring commercial analyses for the GVHD market. You find data, trends and predictions.

Buy our report today Global Graft versus Host Disease (GVHD) Market 2017-2027: Acute, Chronic and Prophylaxis GVHD.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Graft versus Host Disease (GVHD) Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
    • 1.6.1. Primary Research
    • 1.6.2. Secondary Research
    • 1.6.3. Market Evaluation & Forecasting Methodology
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Graft versus Host Disease Background

  • 2.1. Graft versus Host Disease Definition
  • 2.2. Graft versus Host Disease Classifications
    • 2.2.1. Acute graft-versus-host disease (GVHD)
    • 2.2.2. Chronic graft-versus-host disease (GVHD)
    • 2.2.3. Symptoms of Graft versus Host Disease
  • 2.3. Grades of GvHD

3. Global GVHD Market 2016

  • 3.1. Global GVHD Market, 2016

4. Global GHVD Market Forecast, 2016-2027

  • 4.1. Key Findings
  • 4.2. Key Market Challenges and Opportunities

5. Global GVHD Market by Product 2017-2027

6. Regional GVHD Market 2016-2026

  • 6.1. Regional Breakdown of the GVHD Market, 2016
  • 6.2. United States GVHD Market Forecast 2017-2027
    • 6.2.1. U.S. GVHD Market Forecast by Products 2017-2027
    • 6.2.2. U.S. GVHD Patient Number Forecast 2016-2027
  • 6.3. Japan GVHD Market Forecast 2017-2027
    • 6.3.1. Japan GVHD Market Forecast by Products 2017-2027
    • 6.3.2. Japan GVHD Patient Number Forecast 2016-2027
  • 6.4. France GVHD Market Forecast 2017-2027
    • 6.4.1. France GVHD Market Forecast by Products 2017-2027
    • 6.4.2. France GVHD Patient Number Forecast 2016-2027
  • 6.5. Germany GVHD Market Forecast 2017-2027
    • 6.5.1. Germany GVHD Market Forecast by Products 2017-2027
    • 6.5.2. Germany GVHD Patient Number Forecast 2016-2027
  • 6.6. Italy GVHD Market Forecast 2017-2027
    • 6.6.1. Italy GVHD Market Forecast by Products 2017-2027
    • 6.6.2. Italy GVHD Patient Number Forecast 2016-2027
  • 6.7. Spain GVHD Market Forecast 2017-2027
    • 6.7.1. Spain GVHD Market Forecast by Products 2017-2027
    • 6.7.2. Spain GVHD Patient Number Forecast 2016-2027
  • 6.8. United Kingdom GVHD Market Forecast 2017-2027
    • 6.8.1. United Kingdom GVHD Market Forecast by Products 2017-2027
    • 6.8.2. United Kingdom GVHD Patient Number Forecast 2016-2027
  • 6.9. Key Findings
  • 6.10. Treatment Goals

7. Leading Drugs in the Graft versus Host Disease (GVHD) Market 2017-2027

  • 7.1. Temcell HS
    • 7.1.1. Introduction
    • 7.1.2. Safety & Efficacy
    • 7.1.3. Advantages & Disadvantages
    • 7.1.4. Total Temcell Sales, 2016-2027
  • 7.2. Remicade
    • 7.2.1. Introduction
    • 7.2.2. Safety & Efficacy
    • 7.2.3. Advantages & Disadvantages
    • 7.2.4. Total Remicade Sales, 2016-2027
  • 7.3. Lemtrada
    • 7.3.1. Introduction
    • 7.3.2. Safety & Efficacy
    • 7.3.3. Advantages & Disadvantages
    • 7.3.4. Total Lemtrada Sales, 2016-2027
  • 7.4. Velcade
    • 7.4.1. Introduction
    • 7.4.2. Safety & Efficacy
    • 7.4.3. Advantages & Disadvantages
    • 7.4.4. Total Velcade Sales, 2016-2027
  • 7.5. Gleevac
    • 7.5.1. Introduction
    • 7.5.2. Safety & Efficacy
    • 7.5.3. Advantages & Disadvantages
    • 7.5.4. Total Gleevac Sales, 2016-2027
  • 7.6. Rapamune
    • 7.6.1. Introduction
    • 7.6.2. Safety & Efficacy
    • 7.6.3. Advantages & Disadvantages
    • 7.6.4. Total Rapamune Sales, 2016-2027
  • 7.7. Enbrel
    • 7.7.1. Introduction
    • 7.7.2. Safety & Efficacy
    • 7.7.3. Advantages & Disadvantages
    • 7.7.4. Total Enbrel Sales, 2016-2027
  • 7.8. Orencia
    • 7.8.1. Introduction
    • 7.8.2. Safety & Efficacy
    • 7.8.3. Advantages & Disadvantages
    • 7.8.4. Total Orencia Sales, 2016-2027
  • 7.9. Nulojix
    • 7.9.1. Introduction
    • 7.9.2. Safety & Efficacy
    • 7.9.3. Advantages & Disadvantages
    • 7.9.4. Total Nulojix Sales, 2016-2027
  • 7.10. Grafalon (ATG-Fresenius S)
    • 7.10.1. Introduction
    • 7.10.2. Safety & Efficacy
    • 7.10.3. Advantages & Disadvantages
    • 7.10.4. Total ATG-Fresenius Sales, 2016-2027

8. Emerging Therapies in the Graft versus Host Disease (GVHD) Market 2017-2027

  • 8.1. Leukotac (inolimomab)
    • 8.1.1. Introduction
    • 8.1.2. Clinical Development
    • 8.1.3. Total Leukotac Sales, 2016-2027
  • 8.2. Begedina (begelomab)
    • 8.2.1. Introduction
    • 8.2.2. Clinical Development
    • 8.2.3. Total Begelomab Sales, 2016-2027
  • 8.3. Budesonide/Budenofalk (effeverscent)
    • 8.3.1. Introduction
    • 8.3.2. Clinical Development
    • 8.3.3. Total Budesonide/Budenofalk Sales, 2016-2027

9. Global Graft versus Host Disease (GVHD) Market Drivers & Barriers

  • 9.1. Market Drivers
    • 9.1.1. Orphan Designation
    • 9.1.2. Increased clinical & Pre-clinical studies with positive results
    • 9.1.3. Increased Collaborations & Acquisitions
    • 9.1.4. Competition among biotech and pharmaceutical giants
    • 9.1.5. Wide range of targets
  • 9.2. Market Barriers
    • 9.2.1. Side-effects of approved drugs
    • 9.2.2. Economic Burden
    • 9.2.3. Challenges in Drug Development
    • 9.2.4. Social Burden

10. SWOT Analysis

11. Conclusion

  • 11.1. GVHD Market Forecast
  • 11.2. GVHD Regional Market Forecast
  • 11.3. GVHD Market Segments

Associated Visiongain Reports

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1: Global GVHD Market: Revenue($m), AGR(%), CAGR(%) by Region, 2016-2020
  • Table 2.1: Definition of Acute and Chronic GvHD
  • Table 2.2: Glucksberg Clinical Stage of Acute GvHD
  • Table 2.3: Glucksberg Grade of Acute GvHD
  • Table 2.4: Global Scoring of cGvHD
  • Table 3.1: Global GVHD Market: Revenue($m) and Market Share(%) by Segment, 2016
  • Table 4.1: Key Events and their Market Impact(2013-2027)
  • Table 4.2: Global GVHD Market Forecast: Revenue($bn), AGR(%) and CAGR(%), 2016-2027
  • Table 4.3: Global GVHD by Treatment Type Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 5.1: Global GVHD Market Forecast 2016-2027($m), AGR %, CAGR %)
  • Table 6.1: Global GVHD Market: Revenue($m) and Market Share(%) by Region, 2016
  • Table 6.2: United States GVHD Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.3: United States GVHD Market Forecast Segmented by Treatment Type Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.4: U.S. GVHD Market Forecast by Products: Revenue($m), 2016-2027
  • Table 6.5: U.S. GVHD Patient Number Forecast, 2013-2026
  • Table 6.6: U.S. GVHD Patient Number Forecast, 2017-2027
  • Table 6.7: Japan GVHD Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.8: Japan GVHD Market Forecast Segmented by Treatment Type Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.9: Japan GVHD Market Forecast by Products: Revenue($m), 2016-2027
  • Table 6.10: Japan GVHD Patient Number Forecast, 2013-2026
  • Table 6.11: Japan GVHD Patient Number Forecast, 2017-2027
  • Table 6.12: France GVHD Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.13: France GVHD Market Forecast Segmented by Treatment Type Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.14: France GVHD Market Forecast by Products: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.15: France GVHD Patient Number Forecast, 2013-2026
  • Table 6.16: France GVHD Patient Number Forecast, 2017-2027
  • Table 6.17: Germany GVHD Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.18: Germany GVHD Market Forecast Segmented by Treatment Type Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.19: Germany GVHD Market Forecast by Products: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.20: Germany GVHD Patient Number Forecast, 2013-2026
  • Table 6.21: Germany GVHD Patient Number Forecast, 2017-2027
  • Table 6.22: Italy GVHD Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.23: Italy GVHD Market Forecast Segmented by Treatment Type Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.24: Italy GVHD Market Forecast by Products: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.25: Italy GVHD Patient Number Forecast, 2013-2026
  • Table 6.26: Italy GVHD Patient Number Forecast, 2017-2027
  • Table 6.27: Spain GVHD Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.28: Spain GVHD Market Forecast Segmented by Treatment Type Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.29: Spain GVHD Market Forecast by Products: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.30: Spain GVHD Patient Number Forecast, 2013-2026
  • Table 6.31: Spain GVHD Patient Number Forecast, 2017-2027
  • Table 6.32: United Kingdom GVHD Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.33: United Kingdom GVHD Market Forecast Segmented by Treatment Type Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.34: United Kingdom GVHD Market Forecast by Products: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 6.35: United Kingdom GVHD Patient Number Forecast, 2013-2026
  • Table 6.36: United Kingdom GVHD Patient Number Forecast, 2017-2027
  • Table 7.1: Temcell Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.2: Remicade Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.3: Lemtrada Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.4: Velcade Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.5: Gleevac Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.6: Rapamune Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.7: Enbrel Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.8: Orencia Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.9: Nulojix Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 7.10: ATG-Fresenius Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 8.1: Leukotac Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 8.2: Begelomab Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 8.3: Budesonide/Budenofalk Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 11.1: Global Graft versus Host Disease(GVHD) Market: Revenue($m), AGR(%), CAGR(%), 2016, 2022, 2027
  • Table 11.2: Global GVHD Market: Revenue($m), AGR(%), CAGR(%) by Region, 2016, 2022, 2027
  • Table 11.3: Global Graft versus Host Disease(GVHD) Market: Revenue($m), AGR(%), CAGR(%) by Segment, 2016, 2022, 2027

List of Figures

  • Figure 2.1: Initiation and Evolution of GvHD
  • Figure 3.1: Global GVHD Market: Revenue($m) by Segment, 2016
  • Figure 3.2: Global GVHD: Market Share(%) by Segment, 2016
  • Figure 4.1: Global GVHD Market: Revenue($bn) 2016-2027
  • Figure 4.2: Global GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 5.1: Global GVHD Market by product 2016-2027($m)
  • Figure 5.2: Global GVHD Market by Product: Market Share(%), 2016
  • Figure 5.3: Global GVHD Market by Product: Market Share(%), 2022
  • Figure 5.4: Global GVHD Market by Product: Market Share(%), 2027
  • Figure 6.1: Global GVHD Market: Revenue($m) by Region, 2016
  • Figure 6.2: Global GVHD: Market Share(%) by Region, 2016
  • Figure 6.3: United States GVHD market Forecast: 2016-2027($m, AGR %)
  • Figure 6.4: United States GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 6.5: United States GVHD Market by Treatment Type: Market Share(%), 2016
  • Figure 6.6: United States GVHD Market by Treatment Type: Market Share(%), 2022
  • Figure 6.7: United States GVHD Market by Treatment Type: Market Share(%), 2027
  • Figure 6.8: U.S. GVHD Patient Number Forecast, 2013-2026
  • Figure 6.9: U.S. GVHD Patient Number Forecast, 2017-2027
  • Figure 6.10: Japan GVHD market Forecast:2016-2027($m, AGR %)
  • Figure 6.11: Japan GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 6.12: Japan GVHD Market by Treatment Type: Market Share(%), 2016
  • Figure 6.13: Japan GVHD Market by Treatment Type: Market Share(%), 2022
  • Figure 6.14: Japan GVHD Market by Treatment Type: Market Share(%), 2027
  • Figure 6.15: Japan GVHD Patient Number Forecast, 2013-2026
  • Figure 6.16: Japan GVHD Patient Number Forecast, 2017-2027
  • Figure 6.17: France GVHD market Forecast: 2016-2027($m, AGR %)
  • Figure 6.18: France GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 6.19: France GVHD Market by Treatment Type: Market Share(%), 2016
  • Figure 6.20: France GVHD Market by Treatment Type: Market Share(%), 2022
  • Figure 6.21: France GVHD Market by Treatment Type: Market Share(%), 2027
  • Figure 6.22: France GVHD Patient Number Forecast, 2013-2026
  • Figure 6.23: France GVHD Patient Number Forecast, 2017-2027
  • Figure 6.24: Germany GVHD market Forecast: 2016-2027($m, AGR %)
  • Figure 6.25: Germany GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 6.26: Germany GVHD Market by Treatment Type: Market Share(%), 2016
  • Figure 6.27: Germany GVHD Market by Treatment Type: Market Share(%), 2022
  • Figure 6.28: Germany GVHD Market by Treatment Type: Market Share(%), 2027
  • Figure 6.29: Germany GVHD Patient Number Forecast, 2013-2026
  • Figure 6.30: Germany GVHD Patient Number Forecast, 2017-2027
  • Figure 6.31: Italy GVHD market Forecast: 2016-2027($m, AGR %)
  • Figure 6.32: Italy GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 6.33: Italy GVHD Market by Treatment Type: Market Share(%), 2016
  • Figure 6.34: Italy GVHD Market by Treatment Type: Market Share(%), 2022
  • Figure 6.35: Italy GVHD Market by Treatment Type: Market Share(%), 2027
  • Figure 6.36: Italy GVHD Patient Number Forecast, 2013-2026
  • Figure 6.37: Italy GVHD Patient Number Forecast, 2017-2027
  • Figure 6.38: Spain GVHD market Forecast: 2016-2027($m, AGR %)
  • Figure 6.39: Spain GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 6.40: Spain GVHD Market by Treatment Type: Market Share(%), 2016
  • Figure 6.41: Spain GVHD Market by Treatment Type: Market Share(%), 2022
  • Figure 6.42: Spain GVHD Market by Treatment Type: Market Share(%), 2027
  • Figure 6.43: Spain GVHD Patient Number Forecast, 2013-2026
  • Figure 6.44: Spain GVHD Patient Number Forecast, 2017-2027
  • Figure 6.45: United Kingdom GVHD market Forecast: 2016-2027($m, AGR %)
  • Figure 6.46: United Kingdom GVHD Market Forecast Segmented by Treatment Type: 2016-2027($m)
  • Figure 6.47: United Kingdom GVHD Market by Treatment Type: Market Share(%), 2016
  • Figure 6.48: United Kingdom GVHD Market by Treatment Type: Market Share(%), 2022
  • Figure 6.49: United Kingdom GVHD Market by Treatment Type: Market Share(%), 2027
  • Figure 6.50: United Kingdom GVHD Patient Number Forecast, 2013-2026
  • Figure 6.51: United Kingdom GVHD Patient Number Forecast, 2017-2027
  • Figure 7.1: Temcell: Sales($m), 2016-2027
  • Figure 7.2: Remicade: Sales($m), 2016-2027
  • Figure 7.3: Lemtrada: Sales($m), 2016-2027
  • Figure 7.4: Velcade: Sales($m), 2016-2027
  • Figure 7.5: Gleevac: Sales($m), 2016-2027
  • Figure 7.6: Rapamune: Sales($m), 2016-2027
  • Figure 7.7: Enbrel: Sales($m), 2016-2027
  • Figure 7.8: Orencia: Sales($m), 2016-2027
  • Figure 7.9: Nulojix: Sales($m), 2016-2027
  • Figure 7.10: ATG-Fresenius: Sales($m), 2016-2027
  • Figure 8.1: Leukotac: Sales($m), 2016-2027
  • Figure 8.2: Begelomab: Sales($m), 2016-2027
  • Figure 8.3: Budesonide/Budenofalk: Sales($m), 2016-2027
  • Figure 11.1: Global Graft versus Host Disease(GVHD) Market: Revenue($m), 2016, 2022, 2027
  • Figure 11.2: Global Graft versus Host Disease(GVHD) Market: Revenue($m), by Region, 2016, 2022, 2027
  • Figure 11.3: Global Graft versus Host Disease(GVHD) Market: Revenue($m) by Segment, 2016, 2022, 2027

Companies Listed

  • Adienne Pharma & Biotech
  • Amgen, Inc.
  • Bristol Myers Squibb (BMS)
  • Committee for Medicinal Products for Human Use (CHMP)
  • Dr. Falk Pharma GmbH
  • European Commission
  • Fate Therapeutics
  • Fresenius Biotech
  • Genzyme
  • Jazz Pharmaceuticals
  • JCR Pharmaceuticals
  • Johnson & Johnson
  • Kymab Group Limited
  • MolMed
  • Neovii Biotech
  • Novartis
  • OncoImmune
  • Pfizer
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Targazyme, Inc.
  • US FDA
Back to Top